Drug · DIN 02490080
ESPEROCT
Authorized, not yet reported as sold
Authorized for sale in Canada; the company has not yet told Health Canada that it is on the market.
Status Approved since July 4, 2019.
- Drug Identification Number (DIN)
- 02490080
- Company (DIN owner)
- Novo Nordisk Canada IncMississauga, Ontario, Canada
- Schedule
- Schedule d
- Dosage form
- Powder For Solution
- Route
- Intravenous
- Therapeutic class (ATC)
- Coagulation factor viii B02BD02
- Class
- Human
- Record last updated
- May 13, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| ANTIHEMOPHILIC FACTOR VIII (RECOMBINANT, B-DOMAIN TRUNCATED), PEGYLATED | 1500 UNIT | VIAL |
Notices of Compliance
Health Canada approvals that name this DIN.
- July 4, 2019: NOC 22386New Drug Submission (NDS)
Other DINs named ESPEROCT
- DIN 02490064 · Marketed
- DIN 02490072 · Marketed
- DIN 02490099 · Marketed
- DIN 02490102 · Marketed